Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC4 | P56524 | 1/20 | 0.46 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.46 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.46 |
| ▸ | CTSS | P25774 | 2/20 | 0.45 |
| ▸ | CTSK | P43235 | 2/20 | 0.45 |
| ▸ | ITGB3 | P05106 | 10/20 | 0.44 |
| ▸ | ITGA2B | P08514 | 10/20 | 0.44 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | BTK | Q06187 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.38 |
| ▸ | CA1 | P00915 | 1/20 | 0.37 |
| ▸ | CA2 | P00918 | 1/20 | 0.37 |
| ▸ | CA7 | P43166 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1414317 | 1.00 | HDAC4 (0.46) | HDAC4HDAC1HDAC6CTSSCTSK | |
| SCHEMBL28463725 | 1.00 | HDAC4 (0.46) | HDAC4HDAC1HDAC6CTSSCTSK | |
| SCHEMBL25321256 | 0.93 | CTSK (0.42) | HDAC4HDAC1HDAC6CTSSCTSK | |
| SCHEMBL25321261 | 0.93 | CTSK (0.42) | HDAC4HDAC1HDAC6CTSSCTSK | |
| SCHEMBL12139098 | 0.88 | HDAC4 (0.46) | HDAC4HDAC1HDAC6CTSSCTSK | |
| SCHEMBL1414236 | 0.88 | HDAC4 (0.46) | HDAC4HDAC1HDAC6CTSSCTSK | |
| SCHEMBL28964316 | 0.87 | HDAC4 (0.44) | HDAC4HDAC1HDAC6CTSSCTSK | |
| SCHEMBL3363650 | 0.86 | AAK1 (0.43) | CTSSCTSKITGB3ITGA2BKMT2A | |
| SCHEMBL1414251 | 0.86 | AAK1 (0.43) | CTSSCTSKITGB3ITGA2BKMT2A | |
| SCHEMBL6690998 | 0.86 | CTSS (0.47) | HDAC4HDAC1HDAC6CTSSCTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8436006-B2 | 2-amino-quinazoline derivatives useful as inhibitors of β-secretase (BACE) | JANSSSEN PHARMACEUTICA N.V. (BE) | 2013-05-07 | — | — | US | disclosed |
| US-8426607-B2 | Substituted amino-benzimidazoles, medicaments comprimising said compound, their use and their method of manufacture | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-04-23 | — | — | US | disclosed |
| US-8426607-B2 | Substituted amino-benzimidazoles, medicaments comprimising said compound, their use and their method of manufacture | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-04-23 | — | — | US | disclosed |
| US-8426429-B2 | 2-amino-quinazoline derivatives useful as inhibitors of β-secretase (BACE) | JANSSSEN PHARMACEUTICA N.V. (BE) | 2013-04-23 | — | — | US | disclosed |
| US-8383637-B2 | 2-amino-quinazoline derivatives useful as inhibitors of β-secretase (BACE) | JANSSSEN PHARMACEUTICA N.V. (BE) | 2013-02-26 | — | — | US | disclosed |
| US-20110288139-A1 | SUBSTITUTED AMINO-BENZIMIDAZOLES, MEDICAMENTS COMPRIMISING SAID COMPOUND, THEIR USE AND THEIR METHOD OF MANUFACTURE | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-11-24 | — | — | US | disclosed |
| US-20110288139-A1 | SUBSTITUTED AMINO-BENZIMIDAZOLES, MEDICAMENTS COMPRIMISING SAID COMPOUND, THEIR USE AND THEIR METHOD OF MANUFACTURE | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-11-24 | — | — | US | disclosed |
| US-7932261-B2 | Macrocycle derivatives useful as inhibitors of β-secretase (BACE) | JANSSEN PHARMACEUTICA NV (BE) | 2011-04-26 | — | — | US | disclosed |
| US-7932261-B2 | Macrocycle derivatives useful as inhibitors of β-secretase (BACE) | JANSSEN PHARMACEUTICA NV (BE) | 2011-04-26 | — | — | US | disclosed |
| US-7932261-B2 | Macrocycle derivatives useful as inhibitors of β-secretase (BACE) | JANSSEN PHARMACEUTICA NV (BE) | 2011-04-26 | — | — | US | disclosed |
| EP-1789398-A1 | 2-AMINO-QUINAZOLINE DERIVATIVES USEFUL AS INHIBITORS OF B-SECRETASE (BACE) | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-05-30 | — | — | EP | disclosed |
| WO-2007050612-A1 | 2-AMINO-3,4-DIHYDRO-PYRIDO[3,4-D]PYRIMIDINE DERIVATIVES USEFUL AS INHIBITORS OF BETA-SECRETASE (BACE) | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-05-03 | — | — | WO | disclosed |
| EP-1776349-A2 | 2-AMINO-QUINAZOLINE DERIVATIVES USEFUL AS INHIBITORS OF BETA-SECRETASE (BACE) | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-04-25 | — | — | EP | disclosed |
| EP-1776350-A1 | NOVEL 2-AMINO-QUINAZOLINE DERIVATIVES USEFUL AS INHIBITORS OF ß-SECRETASE ( BACE ) | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-04-25 | — | — | EP | disclosed |
| US-20060178383-A1 | Novel 2-amino-quinazoline derivatives useful as inhibitors of beta-secretase (BACE) | JANSSEN PHARMACEUTICA, N.V. (BE) | 2006-08-10 | — | — | US | disclosed |
| US-20060079686-A1 | Novel 2-amino-quinazoline derivatives useful as inhibitors of beta-secretase (BACE) | JANSSEN PHARMACEUTICA NV (BE) | 2006-04-13 | — | — | US | disclosed |
| US-20060079687-A1 | Novel 2-amino-quinazoline derivatives useful as inhibitors of beta-secretase (BACE) | JANSSEN PHARMACEUTICA, N.V. (BE) | 2006-04-13 | — | — | US | disclosed |
| WO-2006024932-A1 | 2-AMINO-QUINAZOLINE DERIVATIVES USEFUL AS INHIBITORS OF B-SECRETASE (BACE) | JANSSEN PHARMACEUTICA, N.V. (US) | 2006-03-09 | — | — | WO | disclosed |
| WO-2006017844-A1 | NOVEL 2-AMINO-QUINAZOLINE DERIVATIVES USEFUL AS INHIBITORS OF β-SECRETASE (BACE) | JANSSEN PHARMACEUTICA, N.V. (BE) | 2006-02-16 | — | — | WO | disclosed |
| WO-2006017836-A2 | 2-AMINO-QUINAZOLINE DERIVATIVES USEFUL AS INHIBITORS OF BETA-SECRETASE (BACE) | JANSSEN PHARMACEUTICA, N.V. (BE) | 2006-02-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110288139-A1 | SUBSTITUTED AMINO-BENZIMIDAZOLES, MEDICAMENTS COMPRIMISING SAID COMPOUND, THEIR USE AND THEIR METHOD OF MANUFACTURE | PSEN1, AADAT, PSEN2 | HDAC4 139/4885HDAC1 750/4885HDAC6 537/4885 |
| US-20060178383-A1 | Novel 2-amino-quinazoline derivatives useful as inhibitors of beta-secretase (BACE) | BACE2, BACE1, APP | HDAC4 2176/4885HDAC1 1874/4885HDAC6 2364/4885 |
| US-20060079687-A1 | Novel 2-amino-quinazoline derivatives useful as inhibitors of beta-secretase (BACE) | BACE2, BACE1, APP | HDAC4 2176/4885HDAC1 1874/4885HDAC6 2364/4885 |
| US-20060079686-A1 | Novel 2-amino-quinazoline derivatives useful as inhibitors of beta-secretase (BACE) | BACE2, BACE1, APP | HDAC4 2176/4885HDAC1 1874/4885HDAC6 2364/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.